Fulcrum Therapeutics (FULC) Treasury Shares (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Treasury Shares data on file, last reported at $90.1 million in Q1 2026.

• Treasury Shares for Q1 2026 came in at $90.1 million, up 102222.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.1 million (up 102222.6% YoY), and the FY2025 annual result was $69.5 million, up 161225.22% from the prior year.
• Treasury Shares advanced to $90.1 million in Q1 2026 per FULC's latest filing, from $69.5 million in the prior quarter.
• Over five years, Treasury Shares peaked at $90.1 million in Q1 2026 and troughed at $43072.0 in Q4 2024.
• A 5-year average of $20.0 million and a median of $88048.0 in 2025 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2024 and 2025: Treasury Shares plunged 42.58% in 2024, then soared 161225.22% in 2025.
• A 5-year view of Treasury Shares shows it stood at $76718.0 in 2022, then declined by 2.22% to $75017.0 in 2023, then sank by 42.58% to $43072.0 in 2024, then soared by 161225.22% to $69.5 million in 2025, then climbed by 29.66% to $90.1 million in 2026.
• Business Quant data shows FULC's Treasury Shares at $90.1 million in Q1 2026, $69.5 million in Q4 2025, and $69.5 million in Q3 2025.